Antisense Inhibition of Apolipoprotein C-III in Patients with Hypertriglyceridemia
Daniel Gaudet(Brigham and Women's Hospital), John J.P. Kastelein(Brigham and Women's Hospital), Brenda F. Baker(Ionis Pharmaceuticals (United States)), Rosanne M. Crooke(Ionis Pharmaceuticals (United States)), Richard S. Geary(Ionis Pharmaceuticals (United States)), Diane Brisson(Université de Montréal), Steven G. Hughes(Ionis Pharmaceuticals (United States)), Veronica Alexander(Ionis Pharmaceuticals (United States)), John D. Brunzell(University of Washington), W. S. Singleton(Ionis Pharmaceuticals (United States)), Mark J. Graham(Ionis Pharmaceuticals (United States)), Karine Tremblay(Université de Montréal), Nicholas J. Viney(Ionis Pharmaceuticals (United States)), Joseph L. Witztum(University of California, San Diego)
Cited by 526
Related Papers
Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease
|New England Journal of Medicine|2017|9.1k
Role of oxidized low density lipoprotein in atherogenesis.
|Journal of Clinical Investigation|1991|2.7k
miR-122 regulation of lipid metabolism revealed by in vivo antisense targeting
|Cell Metabolism|2006|2.1k
A comprehensive classification system for lipids
|Journal of Lipid Research|2005|1.8k
The common PPARγ Pro12Ala polymorphism is associated with decreased risk of type 2 diabetes
|Nature Genetics|2000|1.8k